Filling the Void

Vash, Peter
April 2012
JAMA: Journal of the American Medical Association;4/4/2012, Vol. 307 Issue 13, p1381
Academic Journal
A personal narrative is presented which explores the author's experience of treating Paula's obesity who weighed more than 325 pounds.


Related Articles

  • POHYBOVÁ INTERVENCE JAKOU SOUČÁST LÉČENÍ NADVÁHY A OBEZITY. Poděbradská, R. // Rehabilitation & Physical Medicine / Rehabilitace a Fyzikalni Le;Aug2011, Vol. 18 Issue 2, p50 

    This article contains new aspects of obesity as a disease and an insight into physical activity in treating obesity. Currently, obesity is the most frequent metabolic disease (9) and it is important to search for a common, effective application for its prevention and treatment. Ideally, for a...

  • Obesity in Preschoolers: Behavioral Correlates and Directions for Treatment. Kuhl, Elizabeth S.; Clifford, Lisa M.; Stark, Lori J. // Obesity (19307381);Jan2012, Vol. 20 Issue 1, p3 

    Nearly 14% of American preschoolers (ages 2-5) are obese (BMI = 95th percentile for age and gender), yet this group has received little attention in the obesity intervention literature. This review examines what is known about behavioral correlates of obesity in preschoolers and the...

  • Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Cao, Yihai // Nature Reviews Drug Discovery;Feb2010, Vol. 9 Issue 2, p107 

    Current pharmacotherapeutic options for treating obesity and related metabolic disorders remain limited and ineffective. Emerging evidence shows that modulators of angiogenesis affect the expansion and metabolism of fat mass by regulating the growth and remodelling of the adipose tissue...

  • Inflammatory mechanisms linking obesity and metabolic disease. Saltiel, Alan R.; Olefsky, Jerrold M. // Journal of Clinical Investigation;Jan2017, Vol. 127 Issue 1, p1 

    There are currently over 1.9 billion people who are obese or overweight, leading to a rise in related health complications, including insulin resistance, type 2 diabetes, cardiovascular disease, liver disease, cancer, and neurodegeneration. The finding that obesity and metabolic disorder are...

  • Hypothalamic inflammation in obesity and metabolic disease. Jais, Alexander; Brüning, Jens C. // Journal of Clinical Investigation;Jan2017, Vol. 127 Issue 1, p24 

    Over the last years, hypothalamic inflammation has been linked to the development and progression of obesity and its sequelae. There is accumulating evidence that this inflammation not only impairs energy balance but also contributes to obesity-associated insulin resistance. Elevated activation...

  • Immunologic impact of the intestine in metabolic disease. Winer, Daniel A.; Winer, Shawn; Dranse, Helen J.; Lam, Tony K. T. // Journal of Clinical Investigation;Jan2017, Vol. 127 Issue 1, p33 

    Obesity and diabetes are associated with increased chronic low-grade inflammation and elevated plasma glucose levels. Although inflammation in the fat and liver are established features of obesity-associated insulin resistance, the intestine is emerging as a new site for immunologic changes that...

  • Evaluation of Safety and Anti-obese Activity of a Polyherbal Formulation -- Simlim Capsule. Shah, Bijal N.; Soni, Hardik K.; Patel, Ghanshyam R.; Patel, Pooja D.; Paranjape, Archana N. // International Journal of Pharmaceutical & Phytopharmacological R; 

    Obesity is one the most common and now considered as global health problem which triggers many other metabolic disorders. In the present study, a polyherbal formulation - Simlim Capsule was evaluated for its anti-obesity activity in high fat diet (HFD) induced male Wistar albino rats. It was...

  • MEDICAL ESTABLISHMENT RECOGNIZES NEED TO SUPPRESS INSULIN.  // Life Extension;Sep2004, Vol. 10 Issue 9, p32 

    Reports that the article "Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders" was published in the June 2004 issue of "Current Medicinal Chemistry". Observation that insulin inhibitors can produce side effects and should not be taken on a daily basis;...

  • From Treating Complex Coronary Artery Disease to Promoting Cardiovascular Health: Therapeutic Transitions and Challenges, 2010-2020. Kovacic, J. C.; Fuster, V. // Clinical Pharmacology & Therapeutics;Oct2011, Vol. 90 Issue 4, p509 

    Cardiovascular disease (CVD) has become the most common cause of mortality worldwide. Obesity, insufficient physical exercise, diabetes, and advancing age are major risk factors for developing cardiovascular disease that are currently increasing in prevalence. Nevertheless, significant progress...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics